Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Raphael Pharmaceutical Inc. (RAPH) had Consolidated Net Income/Loss of $-1.52M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-1.52M |
|
-- |
|
-- |
|
$1.51M |
|
$-1.51M |
|
$-0.01M |
|
$-1.52M |
|
$-1.52M |
|
$-1.52M |
|
$-1.52M |
|
|
Consolidated Net Income/Loss |
$-1.52M |
$-1.52M |
|
$-1.51M |
|
$-1.51M |
|
18.67M |
|
18.67M |
|
$-0.08 |
|
$-0.08 |
|
| Balance Sheet Financials | |
$0.03M |
|
$0.00M |
|
$0.00M |
|
$0.03M |
|
$0.77M |
|
-- |
|
-- |
|
$0.77M |
|
$-0.74M |
|
$-0.74M |
|
$-0.74M |
|
18.70M |
|
| Cash Flow Statement Financials | |
$-0.53M |
|
-- |
|
$0.32M |
|
$0.23M |
|
$0.02M |
|
$-0.21M |
|
$0.39M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.03 |
|
-- |
|
-- |
|
-- |
|
-0.06 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.53M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
204.72% |
|
204.72% |
|
-5625.93% |
|
204.72% |
|
$-0.04 |
|
$-0.03 |
|
$-0.03 |
|